HCPLive

Top Medical News Today

EU Regulators Accept Dupilumab for Review
Regeneron and Sanofi’s highly-anticipated atopic dermatitis drug dupilumab, trade name Dupixent, has been accepted by the European Medicines Agency (EMA) for review. The drug has performed well in trials and is considered an impending blockbuster.
Chronic idiopathic urticaria (CIU) typically lasts one to five years. Nevertheless, in 14% of CIU patients, the disease lasts longer than five years, and few predictors of its remission rate are available. However, a pair of Thai investigators recently showed that the results of two simple skin tests could predict two-year remission rates in patients with CIU.
Most patients with severe refractory juvenile ideiopathic arthritis-associated uveitis may get complete remission after six months of treatment with tocilizumab (Actemra/Roche.)
A study out of the University of Pittsburgh identifies significant comorbidity and negative outcomes in those with insomnia and asthma, and finds that even asthmatics who report no nighttime breathing disturbances still face a predisposition to sleeplessness.
Though all obese women are treated as though they are at high risk of getting diabetes during pregnancy, that's not true. Only a quarter of them do. A UK team has figured out how to assess risk.
Patients suffering from irritable bowel syndrome with constipation (IBS-C) may benefit from a new drug, plecanatide, making its way through the approval pipeline.
Why do many men decline to use the pre-exposure prophylaxis (PrEP) (Truvada) to reduce their high risk of the human immunodeficiency virus (HIV) infection? A new survey study out of the United Kingdom may have some of the answers.
It may be possible to boost social interaction in people with autism by using a new therapeutic drug target, University of Pennsylvania researchers say.
A retrospective analysis of nutrition studies showed magnesium can reduce heart failure and diabetes risk. The key is dosage, a team found.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$